EMD527040 - ≥99% , CAS No.851333-14-7

CAS: 851333-14-7 Cat. No.: E650472 Formule: C29H32Cl2N4O5 Poids moléculaire: 587.49
DISPONIBLE À COMMANDE
GRADE & PURITY ≥99%
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
Size
Allemagne (EU)
USA*
Price
Qty
1mg
E650472-1mg
Sur commande · 8–12 semaines
833,81€
5mg
E650472-5mg
Sur commande · 8–12 semaines
2 083,35€
Enter a quantity for the sizes you want to add.
🧪

Why this grade

≥99% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.

🌡

Storage & shipping

Store at -20°C Ships Ice chest + Ice pads Check lot-specific COA for exact specifications.

📋

Quality documents

SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.

📚

Literature proof

Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.

Vue d’ensemble

EMD527040 is a potent and highly selective αvβ6 antagonist with antifibrotic activities. EMD527040 can be used for carcinoma and liver fibrosis research

In Vitro

EMD527040 inhibits binding of recombinant αvβ6 to fibronectin at 6 nM as compared to >9.5 μM for αvβ3 and αvβ5 integrins (IC50 50 ). EMD527040 inhibits the attachment of αvβ6 expressing cells (UCLAP3 cells) to fibronectin at IC 50 of 1.6 μM, as compared to >50 μM for αvβ3 and αvβ5 integrins. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

EMD527040 (intraperitoneal injection; 20-60 mg/kg; week 2 to 6 after BDL) attenuates bile ductular proliferation and peribiliary collagen deposition by 40-50%, induces downregulation of fibrogenic and upregulation of fibrolytic genes, and improves liver architecture and function. EMD527040 significantly reduced liver and spleen weights by 22% and 50%, respectively in Mdr2(Abcb4) -/- mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male adult Wistar rats Dosage: 20-60 mg/kg Administration: Intraperitoneal injection; 20-60 mg/kg; week 2 to 6 after BDL (bile duct ligation) Result: Ameliorated fibrosis progression in rodents with biliary fibrosis.

Form:Solid

IC50& Target:αvβ6 6 nM (IC 50 )

Specifications

Spécifications et pureté
≥99%
Mécanismes biochimiques et physiologiques
EMD527040 is a potent and highly selective αvβ6 antagonist with antifibrotic activities. EMD527040 can be used for carcinoma and liver fibrosis research.
Conditions de stockage de stockage
Store at -20°C
Expédié en
Ice chest + Ice pads
Ce produit nécessite l'expédition en chaîne froide. Les services terrestres et autres services économiques ne sont pas disponibles.
Type d'action
INHIBITOR
Pureté
≥99%
Noms et identifiants
Poids moléculaire 587.49

Documentation

📋 Safety Data Sheet (SDS)

Comprehensive hazard, handling, storage, and regulatory compliance document.

Download SDS →

✅ Certificate of Analysis (COA)

Lot-specific quality data. Enter your lot number to retrieve the exact COA.

Look up COA →

📊 Datasheet

Quick-reference summary of product specifications and applications.

View datasheet →

🔬 Specification Sheet

Full quality attributes and acceptance criteria for this grade.

View spec sheet →

Advanced Data

Certificats (CoA, COO, BSE/TSE et tableau d'analyse)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Propriétés chimiques et physiques
SolubilitéDMSO : 100 mg/mL (170.22 mM; Need ultrasonic)
Calculateurs de solution
Avis

Avis des clients

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.